ImmunoPrecise Antibodies (IPA) announced a strategic collaboration with Ribopro. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating Ribopro’s advanced mRNA-based antigen expression expertise with IPA’s in silico and wet-lab antibody discovery capabilities. Together, the two companies aim to accelerate and enhance the development of novel therapeutics by improving antigen presentation and immune responses, a critical step in antibody discovery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPA:
- ImmunoPrecise Antibodies Announces Leadership Changes to Boost AI-Driven Strategy
- ImmunoPrecise appoints Kamil Isaev to board, names Scheffler Interim CFO
- ImmunoPrecise Antibodies Transfers to Nasdaq Capital Market, Gains Extension
- ImmunoPrecise Antibodies Boosts Financial Position Through Successful Capital Initiatives
- ImmunoPrecise Antibodies Strengthens Financial Position with Strategic Capital Initiatives